ARRY-371797 (PF-07265803)
Phase 3Small molecule
PfizerARRY-371797 (PF-07265803) is one of 22 small molecule programs targeting Dilated Cardiomyopathy. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Dilated Cardiomyopathy
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Rapamune
PPrism Pharmaceuticals
Approved
Lotensin
VValidus Pharmaceuticals
Approved
Atacand
AstraZenecaPhase 3
Coenzyme Q10
MMclean Hospital
Approved
Aceon
Institut de Recherches Internationales ServierPhase 3
Dobutrex
Eli LillyPhase 2
Stem Cell Therapy
UUniversity Hospital, Basel, Switzerland
Phase 3
Ranexa
MMenarini International Operations Luxembourg SA
Phase 2
Zocor
OOrganon and Co
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARRY-371797 (PF-07265803). EMBL-EBI & Wellcome Sanger Institute.
- [4]